Lotte Biologics’ sales amount to KRW 228.6 billion
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.03.21 05:50:33
가나다라
0
The company turned around with a net income for the year amounting to KRW 56.7 billion…The plant mainly produces BMS products
With ‘0 new orders,’ securing new clients has remained a challenge for the company …Lotte Biologics noticed attending the BIO International Convention in June
▲Lotte Biologics.
Lotte Biologics recorded sales of KRW 228.6 billion last year.
As the Syracuse manufacturing plant in the United States went into full-scale production, sales of KRW 83.1 billion in the first half of the year expanded to KRW 145.6 billion in the second half of the year. The analysis indicates that Lotte Biologics’ Contract development and manufacturing organization (CDMO) business is on the right track.
According to the Financial Supervisory Service on the 23rd, Lotte Biologics' sales for last year amounted to KRW 228.6 billion. The company, launched in May 2022, began generating significant revenue last year. Sales for the first quarter were KRW 20.7 billion, KRW 62.3 billion f
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)